journal
MENU ▼
Read by QxMD icon Read
search

Oncology (Williston Park, NY)

journal
https://www.readbyqxmd.com/read/30334243/herb-drug-interactions-in-cancer-care
#1
K Simon Yeung, Jyothirmai Gubili, Jun J Mao
Herbs have served as medicine throughout human history. Since the passage of the Dietary Supplement Health and Education Act (DSHEA), inconsistent regulatory practices have resulted in widespread, indiscriminate use of herbal supplements. Available data indicate that cancer patients use these products (along with standard treatments) more often than the general population. The reasons cited for such use include improving health, reducing the risk of recurrence, and reducing the side effects of cancer treatments...
October 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30334242/approaching-use-of-cdk4-6-inhibitors-in-metastatic-hr-her2-breast-cancer
#2
Jennifer Weiss, Anosheh Afghahi, Elena Shagisultanova, Jennifer R Diamond
No abstract text is available yet for this article.
October 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30334241/gene-expression-assays-in-early-stage-breast-cancer
#3
Joseph A Sparano
No abstract text is available yet for this article.
October 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30334240/when-to-order-an-mri-in-the-initial-evaluation-and-management-of-prostate-cancer
#4
Annerleim Walton-Diaz, Soroush Rais-Bahrami
Prostate cancer remains the only solid tumor diagnosed using transrectal ultrasound-guided sampling of the gland, and not an image-based, lesion-directed approach. This technique has limitations in that it underdiagnoses clinically significant disease and overdiagnoses indolent tumors resulting in overtreatment of patients. Technical advances in MRI in the last decade have made this method the preferred imaging modality for prostate anatomy and for risk assessment of prostate cancer. As of 2018, the indications for MRI in the diagnosis and risk assessment of prostate cancer have expanded from preoperative evaluation to the pre-biopsy setting, as well as for surveillance protocols...
October 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30334239/a-patient-with-egfr-mutated-lung-cancer-progressing-on-erlotinib-evaluating-for-a-t790m-mutation-with-limited-tissue
#5
Emily Wynja, Jenna Hove, Steven F Powell
No abstract text is available yet for this article.
October 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30334238/integrating-immunotherapy-into-colorectal-cancer-care
#6
Cara Wilt, Dung T Le
This article provides guidance on how to incorporate immunotherapy into colorectal cancer care. We review the identification of appropriate patients, available immunotherapy agents, benefits and risks of therapy, and how to overcome potential barriers to access. With recent US Food and Drug Administration approvals of two programmed death 1 (PD-1) receptor inhibitors for use in colorectal cancer, and dual therapy with combined nivolumab (PD-1) and ipilimumab (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] blocking antibody), it is vital that oncology providers be aware of how and when to implement these therapy options...
October 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30334237/managing-psychosocial-distress-lessons-learned-in-optimizing-screening-program-implementation
#7
Elizabeth Ercolano, Emma Hoffman, Hui Tan, Nicholas Pasacreta, Mark Lazenby, Ruth McCorkle
The estimated prevalence of psychosocial distress in cancer patients is 29.6% to 43.4%. Psychosocial distress is associated with depression, a common comorbidity in cancer patients. Untreated distress can contribute to early morbidity and mortality and can worsen other comorbidities. In 2012, the American College of Surgeons (ACoS) Commission on Cancer (CoC) required accredited cancer centers to integrate psychosocial distress screening into cancer care by the end of 2015. Uptake of screening has been minimal, with only 47% to 73% of eligible patients being screened...
October 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30334236/dual-her2-targeting-in-the-adjuvant-setting-where-we-have-been-and-where-we-are-going
#8
Anureet C Copeland, Carey K Anders
Adjuvant human epidermal growth factor receptor 2 (HER2)-directed treatment has changed dramatically over the past decade. Historically, the addition of 1 year of trastuzumab to adjuvant chemotherapy has significantly improved both disease-free survival and overall survival across several studies. More recently, and in the metastatic setting, dual HER2-targeted therapy-beyond that of trastuzumab alone, and in combination with monoclonal antibodies such as pertuzumab and tyrosine kinase inhibitors such as lapatinib-has shown a survival benefit...
October 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30248170/prognostic-value-of-low-tumor-burden-in-patients-with-melanoma
#9
REVIEW
Andrew S Poklepovic, Richard D Carvajal
The therapeutic landscape for cutaneous melanoma has dramatically advanced in the last several years with the development, validation, and approval by the US Food and Drug Administration of several new therapies that have proven effective in treating metastatic disease. Considerable effort has been put into identifying prognostic and predictive markers of therapeutic response to better delineate the patient populations most likely to benefit from treatment. Baseline tumor burden has been described as a common clinical factor associated with treatment response: lower tumor burden at the time of therapeutic intervention is associated with improved responses and survival outcomes on several therapies...
September 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30248169/complications-of-androgen-deprivation-therapy-in-men-with-prostate-cancer
#10
Tejas Patil, Brandon Bernard
The standard treatment for men with metastatic prostate cancer is androgen deprivation therapy (ADT). This therapy is associated with a multitude of side effects that can impact quality of life. These include vasomotor complications (in particular, hot flushes), sexual dysfunction and gynecomastia, osteoporosis, metabolic syndrome, and depression. Additionally, ADT has been associated with neurocognitive deficits, thromboembolic disease, and cardiovascular disease, although the data regarding the latter associations are mixed...
September 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30248168/the-diagnosis-and-management-of-retroperitoneal-sarcoma
#11
Sinziana Dumitra, Alessandro Gronchi
Retroperitoneal sarcoma (RPS) is a rare tumor whose diagnosis and management can be challenging and for which management requires a multidisciplinary team in a specialized center. An important part of the diagnosis-identification of the histologic subtype-depends on pathology; identifying the histologic subtype is important because this can affect prognosis and treatment options. Complete surgical resection with negative margins remains the cornerstone of treatment of nonmetastatic RPS and is the only chance for cure...
September 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30248167/eric-ko-on-combining-radiation-therapy-with-immunotherapy-to-treat-non-small-cell-lung-cancer
#12
Eric Ko
No abstract text is available yet for this article.
September 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30248166/counterpoint-should-radiation-therapy-be-routinely-used-in-the-adjuvant-treatment-of-stage-iii-endometrial-cancer-no-the-literature-does-not-support-routine-use-of-radiation-therapy
#13
https://www.readbyqxmd.com/read/30248165/point-should-radiation-therapy-be-routinely-used-in-the-adjuvant-treatment-of-stage-iii-endometrial-cancer-yes-radiation-therapy-improves-local-control-and-possibly-survival-for-some-patients
#14
Mark E Bernard, Marcus E Randall
No abstract text is available yet for this article.
September 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30248164/dlbcl-cell-of-origin-what-role-should-it-play-in-care-today
#15
REVIEW
Sarah C Rutherford, John P Leonard
Diffuse large B-cell lymphoma (DLBCL) is curable in about two-thirds of patients. Research has focused on determining which patients have less favorable prognoses so that they can be considered for novel targeted-treatment strategies. In 2000, gene expression profiling was used to define two principal DLBCL molecular subtypes, germinal center B-cell-like (GCB) and activated B-cell-like (ABC). Patients with GCB DLBCL have more favorable outcomes than those with ABC DLBCL when treated with standard immunochemotherapy...
September 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30248163/the-adjuvant-treatment-of-stage-iii-colon-cancer-might-less-be-more
#16
REVIEW
James J Lee, Edward Chu
Oxaliplatin-based chemotherapy (FOLFOX [folinic acid, fluorouracil, oxaliplatin] or XELOX [oxaliplatin, capecitabine; also called CAPOX]) for 6 months is the current standard for adjuvant therapy of stage III colon cancer patients with good performance status. However, these regimens are associated with significant toxicities, including myelosuppression, diarrhea, and oxaliplatin-induced, cumulative, dose-dependent neurotoxicity. A reduced duration of adjuvant therapy, which would reduce overall toxicity while maintaining overall clinical efficacy, would be optimal...
September 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30153323/peripheral-t-cell-lymphomas-incorporating-new-developments-in-diagnostics-prognostication-and-treatment-into-clinical-practice-part-2-enktl-eatl-indolent-t-cell-ldp-of-the-gi-tract-atll-and-hepatosplenic-t-cell-lymphoma
#17
REVIEW
Natalia Pin Chuen Zing, Thais Fischer, Jasmine Zain, Massimo Federico, Steven T Rosen
The World Health Organization classification for peripheral T-cell lymphomas (PTCLs) continues to evolve based on genetic and clinical distinctions of each entity. In Part 1, an overview was provided of PTCL not otherwise specified, follicular T-cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma (ALCL), and breast implant-associated ALCL. In Part 2, this review is extended to extranodal natural killer (NK)/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma...
August 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30153322/carboplatin-paclitaxel-induction-in-ovarian-cancer-the-finer-points
#18
Leslie R Boyd, Franco M Muggia
The carboplatin/paclitaxel doublet remains the chemotherapy backbone for the initial treatment of ovarian cancer. This two-drug regimen, with carboplatin dosed using the Calvert formula, yielded convincing noninferior outcomes when compared with the prior, more toxic, regimen of cisplatin/paclitaxel. Carboplatin's dose-limiting toxicity is thrombocytopenia; however, when this drug is properly dosed and combined with paclitaxel, the doublet's cycle 1 dose in chemotherapy-naive women is generally safe. Carboplatin (unlike cisplatin) contributes minimally to the cumulative sensory neuropathy of paclitaxel, thus ensuring noticeable reversibility of neuropathy symptoms following completion of 6 cycles and only occasionally requiring cessation or substitution of the taxane...
August 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30153321/obese-breast-cancer-patients-and-survivors-management-considerations
#19
Jennifer Y Sheng, Dipali Sharma, Gerald Jerome, Cesar Augusto Santa-Maria
Excess body weight is a significant risk factor for many cancers, especially breast cancer. Patients with breast cancer or those with a history of the disease who are overweight or obese have an increased risk of therapy-related morbidity, recurrence, and breast cancer-related mortality. Obesity may also affect quality-of-life factors for survivors, including sexual dysfunction, neuropathy, cardiotoxicity, chronic fatigue, and lymphedema. Most cancer guidelines recommend that breast cancer survivors who are overweight or obese lose weight and that those with a normal body mass index (BMI) maintain a stable body weight...
August 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/30153320/counterpoint-can-chemotherapy-be-eliminated-in-the-treatment-of-follicular-lymphoma
#20
Paul M Barr
No abstract text is available yet for this article.
August 15, 2018: Oncology (Williston Park, NY)
journal
journal
29689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"